维生素C联合硫胺素对脓毒性休克生物标志物的影响:ATESS试验事后分析
该研究为ATESS多中心双盲随机对照试验的事后分析,纳入脓毒性休克患者,治疗组接受静脉维生素C联合硫胺素48小时,对照组为安慰剂。上述标志物对28天死亡率的预测诊断准确性一般。提示该联合方案未显著改变预后相关生物标志物。
要点
- 脓毒性休克早期静脉维生素C联合硫胺素48小时,72小时IL-6、IL-10、AP2、S100β水平与对照组无显著差异。
- 上述四种生物标志物的下降率在治疗组与对照组间无显著差异。
- 基线及72小时生物标志物水平在两组间均无显著差异。
- IL-6、IL-10、AP2、S100β对28天死亡率的预测诊断准确性一般(AUC分析)。
适用人群与场景
- 脓毒性休克患者(ATESS试验纳入人群),来自多中心、双盲、随机对照试验的事后分析。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 治疗组:静脉维生素C联合硫胺素持续48小时;具体剂量、给药频次及目标值原文未提及。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 干预与对照:治疗组静脉维生素C联合硫胺素48小时,对照组为安慰剂。
- 主要终点:72小时IL-6、IL-10、AP2、S100β水平在两组间无显著差异;基线水平也无显著差异。
- 次要终点:上述生物标志物下降率在两组间无显著差异。
- 诊断准确性:上述标志物预测28天死亡率的ROC曲线下面积显示诊断准确性一般。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机对照试验的事后分析(post-hoc study)。
对床旁实践的改变
- 脓毒性休克早期静脉维生素C联合硫胺素48小时未显著改变IL-6、IL-10、AP2、S100β等预后生物标志物水平,不支持以这些标志物变化作为该联合方案疗效的监测指标。
指南或共识出处
- ATESS试验(Ascorbic Acid and Thiamine Effect in Septic Shock),ClinicalTrials.gov NCT03756220。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: We evaluated the effects of vitamin C and thiamine administration on biomarkers in patients with septic shock.
METHODS: This was a post-hoc analysis of the Ascorbic Acid and Thiamine Effect in Septic Shock (ATESS) trial, a multicenter, double-blind, randomized controlled trial. Patients were randomized to either a treatment group (intravenous vitamin C and thiamine for 48 h) or a control group. Interleukin (IL)-6, IL-10, angiopoietin-II (AP2), and S100β were assessed at baseline and at 72 h. The primary outcomes were the biomarker levels at 72 h, and the secondary outcome was reduction rate.
RESULTS: Forty-five patients were assigned to the treatment group and 52 were assigned to the control group. Baseline biomarker levels and at 72 h were not significantly different between the treatment and the placebo groups. The reduction rates were not significantly different between the two groups. These outcome variables showed fair diagnostic accuracy for predicting 28-day mortality according to the area under the receiver operating characteristic curve.
CONCLUSION: Vitamin C and thiamine administration during the early phase of septic shock did not significantly change prognostic biomarker levels of IL-6, IL-10, AP2, and S100β.
TRIAL REGISTRATION: NCT, ClinicalTrials.gov NCT03756220, ATESS. Registered 28 November 2018, https://clinicaltrials.gov/ct2/show/NCT03756220.
参考来源
- Park JE, Jo YH, Hwang SY, et al. Biomarker Analysis for Combination Therapy of Vitamin C and Thiamine in Septic Shock: A Post-Hoc Study of the ATESS Trial. Shock. 2022. PMID: 34482319. doi:10.1097/SHK.0000000000001850
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。